# LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

> **NCT00887588** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 307 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** LCZ696
- **DRUG:** Valsartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00887588
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2015-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00887588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00887588, "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00887588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*